World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
83
Citations
28323
World Ranking
15509
National Ranking
7819

Overview

Bruce W. Bode is affiliated with Emory University in the United States. Their research predominantly focuses on the field of Medicine, with a specialization in Endocrinology, Diabetes and Metabolism. They have contributed extensively to understanding diabetes and its related disorders through a range of clinical studies and research publications.

The scientist's main fields of study and research topics include:

  • Endocrinology, Diabetes and Metabolism
  • Surgery
  • Genetics
  • Cardiology and Cardiovascular Medicine
  • Physiology

  • Diabetes Management and Research
  • Pancreatic function and diabetes
  • Diabetes Treatment and Management
  • Diabetes and associated disorders
  • Hyperglycemia and glycemic control in critically ill and hospitalized patients
  • Adipose Tissue and Metabolism
  • Heart Rate Variability and Autonomic Control

Bode's frequent publication venues highlight the focus of their work and include:

  • Diabetes
  • Diabetes Technology & Therapeutics
  • Diabetes Care
  • Diabetes Obesity and Metabolism
  • Journal of the Endocrine Society

Notable recent papers authored or co-authored by Bruce W. Bode include:

  • "Glycemic Characteristics and Clinical Outcomes of COVID-19 Patients Hospitalized in the United States," 2020, Journal of Diabetes Science and Technology
  • "Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial," 2023, The Lancet
  • "Effect of Continuous Glucose Monitoring on Hypoglycemia in Older Adults With Type 1 Diabetes," 2020, JAMA
  • "American Association of Clinical Endocrinology Clinical Practice Guideline: The Use of Advanced Technology in the Management of Persons With Diabetes Mellitus," 2021, Endocrine Practice
  • "Multicenter Trial of a Tubeless, On-Body Automated Insulin Delivery System With Customizable Glycemic Targets in Pediatric and Adult Participants With Type 1 Diabetes," 2021, Diabetes Care

Frequent co-authors in Bruce W. Bode's research include:

  • Trang T. Ly
  • Anders L. Carlson
  • Jennifer L. Sherr
  • Anuj Bhargava
  • Bruce A. Buckingham

Best Publications

  • Continuous glucose monitoring and intensive treatment of type 1 diabetes.

    Tamborlane Wv;Beck Rw;Bode Bw

  • Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial

    Adrian F Hernandez;Jennifer B Green;Salim Janmohamed;Ralph B D'Agostino

  • Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial.

    Alan Garber;Robert Henry;Robert Ratner;Pedro A Garcia-Hernandez

  • Efficacy of Liraglutide for Weight Loss Among Patients With Type 2 Diabetes The SCALE Diabetes Randomized Clinical Trial

    Melanie J. Davies;Richard Bergenstal;Bruce Bode;Robert F. Kushner

  • Initiating insulin therapy in type 2 Diabetes: a comparison of biphasic and basal insulin analogs.

    Philip Raskin;Elsie Allen;Priscilla Hollander;Andrew Lewin

  • Exercise management in type 1 diabetes: a consensus statement.

    Michael C Riddell;Ian W Gallen;Carmel E Smart;Craig E Taplin

  • Threshold-based insulin-pump interruption for reduction of hypoglycemia

    Richard M. Bergenstal;David C. K Klonoff;Satish K. Garg;Bruce W. Bode

  • Safety of a Hybrid Closed-Loop Insulin Delivery System in Patients With Type 1 Diabetes

    Richard M. Bergenstal;Satish Garg;Stuart A. Weinzimer;Bruce A. Buckingham

  • Glucose Outcomes with the In-Home Use of a Hybrid Closed-Loop Insulin Delivery System in Adolescents and Adults with Type 1 Diabetes.

    Satish K Garg;Stuart A Weinzimer;William V Tamborlane;Bruce A Buckingham

  • Teplizumab for treatment of type 1 diabetes (Protege study): 1-year results from a randomised, placebo-controlled trial.

    Nicole Sherry;William Hagopian;Johnny Ludvigsson;Sunil M Jain

  • Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 1 diabetes (BEGIN Basal-Bolus Type 1): a phase 3, randomised, open-label, treat-to-target non-inferiority trial.

    Simon Heller;John Buse;Miles Fisher;Satish Garg

  • Performance Evaluation of the MiniMed® Continuous Glucose Monitoring System During Patient Home Use

    Todd M. Gross;Bruce W. Bode;Daniel Einhorn;David M. Kayne

  • Hypoglycaemia risk with insulin degludec compared with insulin glargine in type 2 and type 1 diabetes: a pre-planned meta-analysis of phase 3 trials

    R E Ratner;S C L Gough;Chantal Mathieu;S Del Prato

  • Sensor-augmented insulin pump therapy: results of the first randomized treat-to-target study.

    Irl B Hirsch;Jill Abelseth;Bruce W Bode;Jerome S Fischer

  • Continuous subcutaneous insulin infusion and multiple daily injection therapy are equally effective in type 2 diabetes: a randomized, parallel-group, 24-week study.

    Philip Raskin;Bruce W. Bode;Jennifer B. Marks;Irl B. Hirsch

  • Real-Time Continuous Glucose Monitoring Among Participants in the T1D Exchange Clinic Registry

    Jenise C. Wong;Nicole C. Foster;David M. Maahs;Dan Raghinaru

  • New Insulin Delivery Recommendations

    Anders H. Frid;Gillian Kreugel;Giorgio Grassi;Serge Halimi

  • REPLACE-BG: A Randomized Trial Comparing Continuous Glucose Monitoring With and Without Routine Blood Glucose Monitoring in Adults With Well-Controlled Type 1 Diabetes

    Grazia Aleppo;Katrina J Ruedy;Tonya D Riddlesworth;Davida F Kruger

  • International consensus on risk management of diabetic ketoacidosis in patients with type 1 diabetes treated with sodium-glucose cotransporter (SGLT) inhibitors

    Thomas Danne;Satish Garg;Anne L. Peters;John B. Buse

  • Efficacy and safety of a fixed-ratio combination of insulin degludec and liraglutide (IDegLira) compared with its components given alone: results of a phase 3, open-label, randomised, 26-week, treat-to-target trial in insulin-naive patients with type 2 diabetes

    Stephen C L Gough;Bruce Bode;Vincent Woo;Helena W Rodbard

Frequent Co-Authors

Satish K. Garg
Satish K. Garg University of Colorado Anschutz Medical Campus
Irl B. Hirsch
Irl B. Hirsch University of Washington
Simon Heller
Simon Heller University of Sheffield
William V. Tamborlane
William V. Tamborlane Yale University
John B. Buse
John B. Buse University of North Carolina at Chapel Hill
George Howard
George Howard University of Alabama at Birmingham
Ralph B. D'Agostino
Ralph B. D'Agostino Wake Forest University
Leena Mykkänen
Leena Mykkänen The University of Texas Health Science Center at San Antonio
Timothy J. Aitman
Timothy J. Aitman University of Edinburgh

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Beyond traditional paths to becoming a doctor, the healthcare field in the USA offers a variety of online degrees that can lead to rewarding medical careers. These programs can offer greater flexibility, affordability, and accessibility for students who wish to build a career in health services or advance their current qualifications.

For those interested in the administrative side of medicine, pursuing a medical coding certification online can open doors to entry-level roles in hospitals, clinics, and insurance companies. Likewise, registered nurses looking to progress in their field may want to research the most affordable nurse practitioner programs to become licensed nurse practitioners entirely online.

If finding an affordable pathway is your priority, you may be curious about what is the cheapest online college for nursing?. These programs offer accessible routes to becoming a registered nurse. For those pursuing leadership, academic, or advanced clinical roles, there are also online phd nursing programs that build expertise and open up further career opportunities.

Exploring these alternative pathways can help you identify the best route to a fulfilling healthcare career that fits your goals and lifestyle.

Best Scientists Citing Bruce W. Bode

Trending Scientists

Recently Published Articles